Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proactive intermittent 1% benvitimod maintenance for psoriasis recurrence
ChiCTR2500098254Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tapinarof in psoriasis (3 arms), sponsored by Peking University Third Hospital. Primary endpoint: Physician Global Assessment (PGA) score at week 24. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
tapinarof
03
Conditions
psoriasis
Beyond the preview
Go deeper on ChiCTR2500098254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098254.